Principal Investigator
Ali Mouzannar
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20240626
Clinical Trial Summary
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647